J. Crowley

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

C. Paul, Jennifer Clay Cather, Melinda Gooderham et al. · British Journal of Dermatology · 2015 · 479 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study.

Alberto S. Pappo, Shreenal Patel, J. Crowley et al. · Journal of Clinical Oncology · 2010 · 43 citations

Medicine, Oncology, Pharmacotherapy +15

A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas

Shreenal Patel, Alberto S. Pappo, J. Crowley et al. · Journal of Clinical Oncology · 2009 · 37 citations

Medicine, Oncology, Cancer Pharmacology +16

Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey

April W. Armstrong, Emily Edson‐Heredia, Baojin Zhu et al. · Advances in Therapy · 2022 · 15 citations · Full text

Pharmacy, Dermatology, Health Assessment +16